AU2020296063B2 - Targeted protein degradation of PARP14 for use in therapy - Google Patents

Targeted protein degradation of PARP14 for use in therapy

Info

Publication number
AU2020296063B2
AU2020296063B2 AU2020296063A AU2020296063A AU2020296063B2 AU 2020296063 B2 AU2020296063 B2 AU 2020296063B2 AU 2020296063 A AU2020296063 A AU 2020296063A AU 2020296063 A AU2020296063 A AU 2020296063A AU 2020296063 B2 AU2020296063 B2 AU 2020296063B2
Authority
AU
Australia
Prior art keywords
thio
methy1
quinazolin
pyran
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020296063A
Other languages
English (en)
Other versions
AU2020296063A1 (en
Inventor
Kevin Wayne Kuntz
Laurie B. Schenkel
Kerren Kalai Swinger
Melissa Marie Vasbinder
Timothy J. N. Wigle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
AbbVie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Biotechnology Ltd filed Critical AbbVie Biotechnology Ltd
Publication of AU2020296063A1 publication Critical patent/AU2020296063A1/en
Assigned to ABBVIE BIOTECHNOLOGY LTD reassignment ABBVIE BIOTECHNOLOGY LTD Request for Assignment Assignors: RIBON THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2020296063B2 publication Critical patent/AU2020296063B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020296063A 2019-06-19 2020-06-18 Targeted protein degradation of PARP14 for use in therapy Active AU2020296063B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
US62/863,357 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Publications (2)

Publication Number Publication Date
AU2020296063A1 AU2020296063A1 (en) 2021-12-23
AU2020296063B2 true AU2020296063B2 (en) 2026-01-29

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020296063A Active AU2020296063B2 (en) 2019-06-19 2020-06-18 Targeted protein degradation of PARP14 for use in therapy

Country Status (11)

Country Link
US (2) US20220388985A1 (enExample)
EP (1) EP3986887A1 (enExample)
JP (2) JP2022537349A (enExample)
KR (1) KR20220024098A (enExample)
CN (2) CN114206853A (enExample)
AU (1) AU2020296063B2 (enExample)
BR (1) BR112021025645A2 (enExample)
CA (1) CA3142002A1 (enExample)
MA (1) MA56513A (enExample)
SG (1) SG11202112980TA (enExample)
WO (1) WO2020257416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
TW202241426A (zh) * 2021-01-29 2022-11-01 美商律幫治療股份有限公司 治療發炎疾病之方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
MA71624A (fr) 2022-07-29 2025-05-30 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
KR20250055508A (ko) 2022-07-29 2025-04-24 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 치료에 사용하기 위한 parp14의 표적 단백질 분해
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
MY180775A (en) * 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
EP3580212A4 (en) * 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Also Published As

Publication number Publication date
JP7844707B2 (ja) 2026-04-13
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
EP3986887A1 (en) 2022-04-27
WO2020257416A1 (en) 2020-12-24
AU2020296063A1 (en) 2021-12-23
BR112021025645A2 (pt) 2022-02-01
KR20220024098A (ko) 2022-03-03
SG11202112980TA (en) 2021-12-30
CN114206853A (zh) 2022-03-18
CA3142002A1 (en) 2020-12-24
CN120398840A (zh) 2025-08-01
US20220388985A1 (en) 2022-12-08
JP2022537349A (ja) 2022-08-25
JP2025102917A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
US20260125362A1 (en) Targeted protein degradation of parp14 for use in therapy
US11958837B2 (en) Quinazolinones as PARP14 inhibitors
JP2025505882A (ja) Ｐａｒｇの阻害物質
JP6172143B2 (ja) 含窒素二環式芳香族へテロ環化合物
JP2020521818A (ja) プロテインキナーゼ阻害剤として有用なカルボン酸誘導体
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
HK40039341B (en) Quinazolinones as parp14 inhibitors
HK40039341A (en) Quinazolinones as parp14 inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE BIOTECHNOLOGY LTD

Free format text: FORMER APPLICANT(S): RIBON THERAPEUTICS, INC.